Small clinical trial shows promise in pancreatic cancer vaccine, story in New York Times reports

Using a vaccine aimed at each patient's tumor may have delayed the return of pancreatic cancer in half of those who received it in a small clinical trial.

According to a story by Benjamin Mueller in editions of The New York Times from a while ago that I just came across, a study in Nature, "was a landmark in the…movement to make cancer vaccines tailored to the tumors of individual patients."

Dr. Anirban Maitra

Dr. Anirban Maitra, specialist in the disease at the University of Texas MD Anderson Cancer Center, who was not involved in the study, is quoted as saying, "This is the first demonstrable success — and I will call it a success despite the preliminary nature of the study — of an mRNA vaccine in pancreatic cancer. By that standard, it's a milestone."

The study only dealt with 16 White patients who were given the vaccine as part of a treatment that also "included chemotherapy and a drug intended to keep tumors from evading people's immune responses," Mueller's story indicated.

Five years ago, when researchers at Memorial Sloan Kettering Center in New York extracted tumors and shipped samples of them to Germany, the study started. In that country, scientists at BioNTech, the company that made a Covid vaccine with Pfizer, analyzed the genetic makeup of certain proteins on the surface of the cancer cells. BioNTech scientists then produced personalized vaccines "designed to teach each patient's immune system to attack the tumors," the Times story reported.

The piece also quoted Dr. Ira Mellman, vice president of cancer immunology at Genentech, which developed the pancreatic cancer vaccine with BioNTech, as saying, "Just establishing the proof of concept that vaccines in cancer can actually do something after, I don't know, 30 years of failure is probably not a bad thing. We'll start with that."

More information about medical research can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten, aimed at male caregivers. 

Next big advance may be new cancer vaccines that could treat cancers in a variety of organs

Research may be turning a corner, with many scientists predicting new cancer vaccines that would work within five years on breast, lung, ovarian, skin, and pancreatic cancers.

According to a recent Associated Press story by Carla K. Johnson, "these aren't traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back." 

Dr. James L. Gulley

The article quotes Dr. James L. Gulley, who helps lead the Center for Cancer Research at the National Cancer Institute that developed immune therapies, including cancer treatment vaccines. He says, "We're getting something to work. Now we need to get it to work better."

Cancer vaccines, like other immunotherapies, boost the immune system to find and kill cancer cells. For a vaccine to work, the piece quotes Dr. Nora Disis of UW Medicine's Cancer Vaccine Institute in Seattle as saying, it needs to teach the immune system's T cells to recognize cancer as dangerous. "If you saw an activated T cell, it almost has feet. You can see it crawling through a blood vessel to get out into the tissues," she said.

Dr. Steve Lipkin, a medical geneticist at New York's Weill Cornell Medicine, also is quoted: "Vaccines are probably the next big thing. We're dedicating our lives to that."

More information about vaccines can be found in Rollercoaster: How a man can survive his partner's breast cancer, a VitalityPress book that I, Woody Weingarten, aimed at male caregivers.

Cancer vaccines are new type of immunotherapy that might help in fight against breast cancer

Virtually everyone's talking about vaccines, pro and con, regarding Covid-19 but other vaccines merit major attention as well.

According to an article by Cynthia Weiss of the Mayo Clinic News Network in today's daily Marin Independent Journal, cancer vaccines are "another type of immunotherapy that is being developed and tested for breast cancer."

Weiss' story goes on to say that such vaccines can "help train the immune system to see and 'memorize' antigens, or proteins, found on the surface of cancer cells, so that the immune system can fight these antigens if encountered in the future."

The vaccines, the piece adds, "are being studied in different breast cancer settings: treatment of current cancer; prevention of cancer recurrence; or to decrease the risk of cancer spreading to another part of the body, or metastasis."

Dr. Pooja Advani

Weiss' piece is a question-and-answer format with facts supplied by Dr. Pooja Advani, a Mayo Clinic oncologist and hematologist in Jacksonville, Florida.

Immunotherapy, not incidentally, is a comparatively new treatment for breast cancer that's also been used in treating lung and kidney cancers as well as melanomas. 

It "harnesses the body's immune system to help fight cancer," the Mayo Clinic information indicates.

Currently, Advani's information states, "immunotherapy is approved primarily for patients with metastatic or locally advanced triple-negative breast cancer, which is an aggressive subtype of breast cancer, representing 10%-15% of breast cancer, with limited treatment options other than chemotherapy."

Immunotherapy is not immune to side effects, however. Typical ones, according to the story, "can include fatigue, chills, body aches, injection site pain, infusion-related reaction, headache, flu-like symptoms and gastrointestinal symptoms."

And that's not all. Weiss' Q&A piece asserts that immunotherapy "also can affect live function tests; cause respiratory symptoms, such as shortness of breath, cough and fever; cause symptoms of overactive or underachieve thyroid glad, or adrenal gland; and rash."

But most of those symptoms, it should be noted, "are mild to moderate and reversible, if detected early and treated in a timely manner."  

More information about recent treatments can be found in "Rollercoaster: How a man can survive his partner's breast cancer," a VitalityPress book that I, Woody Weingarten, aimed at male caregivers.